Importantly, our findings suggested that the EMThigh-NOS subtype was driven by intrinsic somatic alterations which could be treated by cell cycle targeting strategies, whereas the EMThigh-AKT subtype was driven by the crosstalk between tumor and TME which could be treated by ICB combined with TME remodeling. The gene discussed is AKT1; the disease is neoplasm.